Skip to main content

The Superdevice for Depression

Fisher Wallace Labs is the leading developer of wearable brain stimulation technology for the treatment of depression and other neuropsychiatric and cognitive disorders. The commercial version of our Version 2.0 technology, called OAK, was designed in collaboration with the teams behind Beats and Nest, and is intended to become the first “superdevice” for mental health that achieves smartphone scale.

Sign Up

Clinically Proven

Fisher Wallace completed a 255-subject, triple-blind, randomized, sham-controlled trial that demonstrated rapid effectiveness in treating depression (highly effective in the first seven days) without causing serious side effects; results will be published in The Journal of Clinical Psychiatry. We are now collaborating with world-class researcher partners to conduct a final study for FDA approval. Building towards a future in which our technology is approved to treat a universe of conditions, Fisher Wallace recently completed an anxiety treatment study with the Seattle Police Department, and is currently applying for an Alzheimer’s research award. 

Sign Up

$40M Proof-of-Concept

Under temporary FDA clearance, our Version 1.0 (proof-of-concept) technology was distributed to over 90,000 patients via 14,000 prescribers, generating $40 million in revenue, and obtained Medicaid reimbursement (MaineCare). 

Sign Up


Kelly Roman


Kelly has helped pioneer the wearable brain stimulation category since 2009, with a focus on innovative product development and clinical research. The results of the company's most recent trial will be published in The Journal of Clinical Psychiatry and validate its Version 2.0 wearable, OAK, as one of the most rapid treatments for depression.

Kelly led OAK's industrial design and engineering in collaboration with the teams behind Beats, Nest and the Microsoft HoloLens. Most recently, Kelly partnered with Dr. Maurizio Fava, Psychiatrist-in-Chief of Massachusetts General Hospital, to design and conduct a pivotal depression trial in support of FDA approval.

Directors & Advisors

Chip Fisher


After graduating from Harvard and serving as a sales executive at IBM, Chip acquired the original intellectual property to the Fisher Wallace Stimulator and is the company’s CFO and largest shareholder - and a recent TEDx contributor.

Simon Webster


Simon is CEO of Vistra and founder of SHUFL Capital, a seed investing platform. He previously led CPA Global (IP software and services) as CEO through its merger with Clarivate.

Maurizio Fava, MD


Dr. Fava is Psychiatrist-In-Chief, Department of Psychiatry, at Massachusetts General Hospital, and Director, Division of Clinical Research, at Mass General Research Institute.

David Shulkin, MD


Dr. Shulkin is a former US Secretary of Veterans Affairs and a former CEO of Beth Israel Medical Center.

Michael Greenberg, MD, MPH, FACEP


Mike is an emeritus professor of emergency medicine at Drexel University College of Medicine and a professor of public health in Drexel's Dornsife School of Public Health.

Scott Witt


Scott is a Brand and Creative executive operator who previously served as Creative Director at Apple, advisor to Peloton and Chief Brand Officer at Twill.

Neil Liebowitz, MD, JD


Neil recently served as Chief Medical Officer for two game-changing mental healthcare companies: Talkspace and Beacon Health Options.

Join Us

We are a patient-owned healthcare company

Back to top